POPULARITY
9 episodes with orum
6 episodes with orum
6 episodes with orum
4 episodes with orum
3 episodes with orum
3 episodes with orum
2 episodes with orum
2 episodes with orum
2 episodes with orum
A trip to China, a meeting with the boy emperor, and a terrifying dragon. In this episode, we examine Season 1, Episode 10 of The Mummy: The Animated Series, titled The Boy Who Would Be King.Email: mummymoviepodcast@gmail.comPatreon: https://patreon.com/MummyMoviePodcast?Bibliography:Bracken, G., & Orum, A. (2019). Forbidden City, The. The Wiley Blackwell Encyclopedia of Urban and Regional Studies, 1-6.Chunhua, Y. A. N. G. (2015). China's Emperor Culture in Subtitle Translation: A Case Study of The Last Emperor. Cross-Cultural Communication, 11(3), 73-77.Zhang, Q. (2015). An introduction to Chinese history and culture. Heidelberg: Springer. Hosted on Acast. See acast.com/privacy for more information.
In this episode, Jason Dorfman shares a solid cold calling framework, proven tactics for leveling up your cold calls, and effective strategies for managing sales teams. Check out more free content and get coaching at https://outboundsquad.com
Send us a textIn this episode we interview Ting Ting, Head of Marketing at Orum, a Series B startup transforming sales tech through real-time, phone-based pipeline generation.What you'll learn in this episode:Why authenticity now outweighs polish in B2B marketingHow consumer trends are reshaping professional content strategiesTactical ways to blend thought leadership with brand messagingThe art of empowering employees to create content without going off-brandHow “low-production” video is redefining trust in B2B spacesPractical insights on internal enablement and user-generated advocacyWhat it means to “dogfood” your product and turn it into internal gold
During the Asia-focused Episode 26 of Biotalk, Geoff Meyerson, CEO of Locust Walk, shares fresh insights from Japan, China, and Korea, as featured in our 2025 Q1 Report: Global Trends in Biopharma Transactions Report. Japan saw modest market recovery, a $3.3B buyout of Mitsubishi Tanabe, and lighter licensing activity. Early-stage financings picked up as investors re-engaged. China shifted from IPO optimism to global deal-making as markets cooled. Notable trends included strong out-licensing ($17.6B), AstraZeneca's $2.5B investment, and Ascentage's NASDAQ debut backed by Takeda. Venture activity rebounded, driven by insider-led late-stage rounds. Korea drew attention with Orum's IPO, early-stage deals, and a growing focus on CDMO by major players.Listen now to gain insights into the evolving global biopharma landscape, explore our report, and we welcome the opportunity to discuss its contents with you.
Cultura em Pauta #900 14/02/2025
Cold calling is making a comeback. Enterprise sales has changed. And taking prospects to the World Series might just be the smartest move in sales.In this episode, Colin Specter, VP of Sales at Orum, breaks down how he helped scale a bootstrapped startup into a Series B+ sales powerhouse—and why relationship-driven sales is more important than ever.Does taking a prospect to the World Series make sense? Colin explains why high-touch engagement wins big deals—and why an $8,000 investment on client experiences can outperform digital lead gen.Why cold calling isn't dead. AI has flooded inboxes, making voice the next frontier. Find out why sales teams are doubling down on live conversations.Orum's go-to-market edge: Why their "pilot-first" approach closes faster than traditional sales cycles.The #1 mistake sales leaders make when moving upmarket. Colin shares why some startups fail at enterprise sales—and how to avoid those missteps.Forget MEDDIC—why Orum created its own framework (MEADFIC) and what's missing in your sales process.Full-cycle selling is back: Why top AEs are generating their own pipeline—no matter how full their calendar is.Watch until the end to hear Colin's biggest leadership lesson- and why your sales team should start thinking like CEOs of their own territories.
In today's episode, Djavaneh Bierwirth and Kimberly Zhang welcome Stephany Kirkpatrick, the Founder and CEO of Orum, for an exciting discussion about the future of payments, entrepreneurship, and the role of technology in financial infrastructure. Stephany shares her journey as a non-technical founder, her mission to transform how money moves, and her perspective on the evolving U.S. payments landscape. Tune in to hear about: • The $80 trillion opportunity to make money move by modernizing payments infrastructure • How Orum is simplifying and accelerating payments with unified API-based solutions • The challenges and advantages of being a solo, non-technical founder in the fintech space • Stephany's vision for the future of payment orchestration and how faster payments will redefine business operations
Join FPC Executive Director and CEO Reed Luhtanen as he goes off the rails with Stephany Kirkpatrick of Orum and Dean Nolan of SRM. The trio discusses the potential for B2B instant payments, in particular in light of the recent announcement from the clearing house increasing the RTP limit to $10M.Previous episodes featuring Stephany and Dean:Stephany: https://podcasts.apple.com/us/podcast/12-oct-2023-stephany-kirkpatrick-of-orum-on-account/id1553535872?i=1000631043284Dean: https://podcasts.apple.com/us/podcast/27-oct-2022-moa-agrell-of-trustly-and-dean-nolan/id1553535872?i=1000584042369
See MoreIn this episode of Fintech Confidential, recorded live at the 2024 Money 20/20 event in Las Vegas, Tedd Huff and Stephany Kirkpatrick, founder and CEO of Orum, dive into the world of money movement technology. The discussion flows naturally, covering the many ways Orum is simplifying payments and enhancing access to funds. Kirkpatrick brings a unique perspective, sharing how her background as the daughter of an immigrant and a former financial planner shaped her understanding of money access and inspired her to start Orum.Key Highlights
Welcome to Season 3 of 10/10 GTM: The Podcast for Revenue Leaders! Our guest for Episode 58 is Colin Specter, SVP of Revenue at Orum. Before joining Orum five years ago, Colin led sales teams at Namely and brings over a decade of leadership experience to the conversation. In this episode, Ross and Colin discuss why driving excellence in sales boils down to your attitude and activity, and how well you quality your time. Listen to the episode here, and get the key takeaways from our conversation below.
Sales and Customer Success (CS) teams are the dual engines of revenue growth, yet too often they operate in silos, each with separate goals. Daisy Chung, Head of Revenue Strategy at Orum, underscores that revenue growth comes from a synchronized approach between these two departments. Highlights include: Examples of Sales and CS Not Working Together (07:08), How to Align Product with Customer Success (23:02), And more… Are you looking to create repeatable, scalable, and predictable revenue? We can help! ► https://predictable.fm/get-growth
In this episode, we're sharing the audio from our recent webinar on the current state of sales development. Colin Specter, SVP of Revenue at Orum, joined us to discuss 2024 trends and offer insights and predictions for 2025. Check out the show notes, more free content, and get coaching at https://outboundsquad.com
In a series of podcasts taped live at 2024's Money 20/20 in Las Vegas, host Lou Carlozo brings you the latest from one of the premier financial services conferences in the world. Lou speaks from the Money Pot booth with Stephany Kirkpatrick, Founder and CEO of Orum. It's a fascinating episode that embraces topics from speed and security in fast payments to how Stephany has embraced her role as a first-time CEO learning to lean on others to creat a powerhouse payments company.
"Right at the point when you're feeling exhausted and really bored about promoting a piece of content is right when the market is actually starting to see it," says Adam Sockel, Content Marketing Lead at OrumIn this episode of The Content Cocktail Hour, Adam Sockel, Content Marketing Lead at Orum, talks about the world of content creation and strategy, revealing why he believes the key to memorable content is to be "anything but boring." Adam shares how he navigates the relationship between sales and marketing to the practicalities of running large-scale surveys. He also discusses the importance of maintaining a cohesive brand voice and the real power of proprietary data in content marketing.In this episode, you'll learn:The value of being memorable over being flawlessHow to ensure that your sales development team is consistently aligned with your content strategyInvesting in unique, proprietary data can deliver extraordinary ROIResources:Connect with Jonathan on LinkedIn: https://www.linkedin.com/in/jonathan-gandolf/ Check out The Juice HQ: https://www.thejuicehq.com/ Connect with Adam on LinkedIn: https://www.linkedin.com/in/adam-sockel/Check out Orum: https://www.orum.com/Timestamps:(00:00) Avoiding apathy in marketing strategy(05:38) The impact of centralized customer marketing on sales(12:52) How to create and measure content success(23:07) Why outbound is not dead
Most would agree, there's always room for growth in making our outreach strategies stronger.Expert GTM analyst, Morgan Smith, is joining us to reveal the “hidden skillset” that's changing the game in outreach messaging, and to show us some of the finer points of strategic market segmentation.You'll walk away with strategies to create stronger messaging and ensure your value proposition targets your potential customer's pain points more effectively. You'll Learn:How to identify the best markets to targetWays to find key pain points to use in your value propositionHow to tailor your messaging to diverse audience segmentsThe Speakers: James Buckley and Morgan SmithIf you want to catch The Daily Sales Show live, join hereFollow Sell Better to get the latest actionable tactics from sales pros at the top of their gameExplore our YouTube ChannelThank you to our sponsors: Orum and ZoominfoLooking to up your sales skills?Sales Training for YOU: Use code SELLBETTER to save $200 off your yearly membershipSales Training for your TEAM
Too many times, prospects feel that discovery is nothing more than an interrogation. They're put on the spot to tell you all about their business, but gain very little value in return. It's no wonder so many of these calls end in indecision.In this Daily Sales Show episode, sales experts (and known rivals!) Jen Allen-Knuth and Kyle Asay are joining us to share their proven methods for having natural discovery conversations that make the prospect feel like you “get it.” Learn how to show them that you understand their problems and have a specific, relevant solution.You'll Learn:How to identify and reach the true goals of discoverySpecific questions you can ask to make the conversation valuable for both sidesStrategies for ongoing discovery, multithreading, and better customer relationshipsThe Speakers: Will Aitken, Jen Allen-Knuth and Kyle AsayIf you want to catch The Daily Sales Show live, join hereFollow Sell Better to get the latest actionable tactics from sales pros at the top of their gameExplore our YouTube ChannelThank you to our sponsors: Gong, Orum and AlignedLooking to up your sales skills?Sales Training for YOU: Use code SELLBETTER to save $200 off your yearly membershipSales Training for your TEAM
Episode 429 features Stephany Kirkpatrick, who founded Orum in 2019 on the belief that consumers should have immediate access to their money.Find Stephany Online:Website: https://www.orum.io/Linkedin: https://www.linkedin.com/company/helloorumTwitter: https://twitter.com/StephKirkpat
You've put in the work, and your prospect agrees to a meeting. Fantastic!But then the meeting time comes and goes, and they didn't show up, you've been ghosted. Now what?Richard Smith, Head of Growth at MySalesCoach, is joining us to share what you can do if you're faced with this situation. Plus, he's walking us through his proven strategies to avoid no-shows in the first place and proactively avoid this situation. You'll Learn:How to ensure when booking the meeting that they will make itStrategies before the meeting to guarantee they attend the meetingWhat to do if prospects don't show up to a meetingThe Speakers: Will Aitken and Richard SmithIf you want to catch The Daily Sales Show live, join hereFollow Sell Better to get the latest actionable tactics from sales pros at the top of their gameExplore our YouTube ChannelThank you to our sponsors: Orum and Aligned
Sarah Reece, Director of Demand Generation at Orum, joins Dustin on this week's episode to discuss why you should focus on revenue over leads. They dive into the intricacies of balancing brand awareness and demand creation, the challenges of aligning marketing and sales efforts, and the innovative strategies she's implementing at Orum. You can reach out to Sarah via her LinkedIn profile if you have any questions or insights on the topics discussed today. Also, check out Orum's website to learn more about their work.
Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.The ongoing debate over how countries should handle the H5N1 influenza outbreak is intensifying. U.S. officials have confirmed four cases of livestock-to-human transmission but are not recommending a vaccine push for farm workers. Health officials in Finland have started offering H5N1 vaccines to those in close contact with potentially sick animals. While the CDC is taking a "wait-and-see" approach, many public health officials believe they should reconsider in case severe cases emerge. The U.S. government has bolstered its stockpile of H5N1 vaccines and provided funding for Moderna's development of an mRNA shot for influenza strains, including H5N1.Merck's RSV antibody contender showed success in a late-stage study, while a startup led by former J&J executives raised $165 million for cancer and immune disease drugs. The US government declined to clear Bluebird's fertility support for Zynteglo patients, and private biotech M&A activity is surging amid a difficult IPO market. The advanced therapies field is on the brink of disruption through manufacturing automation, with over 1,000 trials in development. Additionally, pharma companies are competing in the GLP-1 drug race to treat obesity, a market projected to surpass $100 billion by the end of the decade.The biotech industry is experiencing several key developments. Sionna plans to revive AbbVie's cystic fibrosis drugs to compete with Vertex, Artiva's successful IPO raised $167 million for autoimmune cell therapy, NGM secured a private raise of $122 million for revised research plans, and Vertex partnered with Orum to find better "preconditioning" drugs. Cardurion also raised $260 million to advance heart drugs. The private biotech M&A market is surging due to challenges in the IPO market, with acquisitions of mature drug startups on the rise. Overall, the industry is seeing significant activity in drug development, funding rounds, and strategic partnerships to advance therapies and treatments.
In this episode, Aaron Milner, Enterprise Account Executive at Orum, and Jason Dorfman, CEO at Orum, join us to share their expertise on scaling a tech business. Jason discusses his approach to recruiting top talent and the critical role it plays in a startup's success. Aaron provides insights into sales strategies and the impact of a robust SDR team. Connect with AaronConnect with JasonLearn more about Orum School of Podcasting -Launch, Grow, Monetize Your PodcastYou're don't know where to learn to podcast. Now You do. Click the link.Listen on: Apple Podcasts Spotify Follow us on LinkedIn Connect with Scott Connect with Jeff Connect with Eric Grow your business with Abstrakt Join the Abstrakt team Email us Thanks for listening!
Colin Specter is the VP of Sales at Orum, an AI-powered Live Conversation Platform for sellers. He joins the Sales Players to share his journey from working as a valet to leading a high growth, high performance sales team. SPONSORS: • Surfe (Connect your CRM with LinkedIn in 60 seconds) - https://www.surfe.com/?kfl_ln=jesse-woodbury use this link with promo code JWSURFE5 for a 5% discount on your first year • Apollo (Find, contact, and close your ideal buyers) - https://apollo.partnerlinks.io/ofi3s6f32xsj EPISODE LINKS: • Connect with Colin on LinkedIn: https://www.linkedin.com/in/colinspecter/ • Get Orum: https://www.orum.com/ CONNECT WITH JESSE: • Linkedin: https://www.linkedin.com/in/jessewoodbury/ • Twitter: https://twitter.com/jessewoodbury • Website: https://jessewoodbury.com/ CONNECT WITH CHASE: • Linkedin: https://www.linkedin.com/in/chase-barmore • Twitter: https://twitter.com/ChaseBarmore?s=20 • Website: https://chasebarmore.com HELP US GROW SP: • Join Sales Players MVP: https://www.skool.com/salesplayers • Subscribe! • Leave a rating, write a review, and share • Check out the above sponsors, it's the best way to support the show GUEST HIGHLIGHTS: Ian Koniak, Brandon Fluharty, Scott Leese, Jamal Reimer, Jen Allen-Knuth, Andy Paul, Collin Mitchell, Rafael Figueroa, Tim Zielinski, Christian Banach, Rajiv 'RajNATION' Nathan, Belal Batrawy, Christine Rogers, Chris Beall, Dustin Brown, Patrick Baynes, Jeroen Corthout, Nate Nasralla, Gabe Lullo, Vince Beese, Brandon Bornancin, Girish Redekar, Guillaume Moubeche, Lloyed Lobo, Corey Quinn, Danny Delvecchio, Tom Slocum
Sales Game Changers | Tip-Filled Conversations with Sales Leaders About Their Successful Careers
This is episode 661. Read the complete transcription on the Sales Game Changers Podcast website. Read more about the Institute for Excellence in Sales Premier Sales Employer (PSE) designation and program here. Purchase Fred Diamond's best-sellers Love, Hope, Lyme: What Family Members, Partners, and Friends Who Love a Chronic Lyme Survivor Need to Know and Insights for Sales Game Changers now! Register for the IES Women in Sales Leadership Development programs here. Today's show featured an interview with Greg Lullo, CEO of Alleyoop, and his customer, Terry Husayn, VP of Engagement at live conversation company Orum. GABE'S ADVICE: “You have to be practicing and you have to be consistently, consistently, consistently rehearsing that. I remember driving to work every single day when I was an SDR. My steering wheel was my best prospect. I was the guy like, “Who is that crazy person talking to himself on the way to work?” That was me because I was practice, drill, rehearse, practice, drill, rehearse. It's second nature. Again, preparing what to say and don't be lazy in language is super important.” TERRY'S ADVICE: “Business process map the processes the SDRs are taking a day, whether it's prospecting, demos, follow ups, or proposals for AEs. You have no idea how much time is wasted not selling. You also have all the tools. You likely have the Salesforce, ZoomInfos and Gongs and everything. You have the exact same tech stack that your competitors do, but your competitor probably is automated twice as much as you have. Take a look at your rev ops stack, look at what your team is doing. I guarantee you there's 50% plus more efficiency there that you just haven't even deployed.”
This episode is the audio from our recent webinar on AE Self-Sourcing. We were joined by Aaron Milner from Orum and Kyle Parrish from Mixmax and walked through a framework that will help you self-source 30%+ of your pipeline. Check out the show notes, more free content, and get coaching at https://outboundsquad.com
This episode is the audio from our recent webinar on multi-threading. We were joined by Richard Harris, Krysten Conner, and Colin Specter from Orum. Check out the show notes, more free content, and get coaching at https://outboundsquad.com
This episode is the audio from our recent webinar on Discovery: From problem to payoff: Steal this framework to build urgency, and close larger deals (and never get ghosted again). We were joined by Aaron Barkman, Strategic Account Executive at Orum, and Nate Nasralla, Co-founder at Fluint. Check out the show notes, more free content, and get coaching at https://outboundsquad.com
[Original air date, Nov 8, 2022] Miguel Armaza sits down with Matt Harris, Partner at Bain Capital Ventures and one of the Fintech OG legends who started his investing career back in 1995 and has been working with fintech entrepreneurs throughout several cycles. Some of his investments include GoCardless, Orum, Finix, Acorns, and many more.In this episode, Miguel stops by the Bain Capital Ventures office in New York City, where they discuss:Investing through economic cycles. Matt was a fintech VC during the Dot-com bubble - what did he learn once the bubble burst and what should young VCs keep in mind today?B2B vs B2C Fintech. Matt overwhelmingly prefers backing B2B companies with little to no credit risk. Why is that?The Future of fintech and why Bain is excited about the potential of embedded financeWhat makes a great investor, how founders should think about their board, why NYC is the capital of fintech… and a lot more!Want more podcast episodes? Join me and follow Fintech Leaders today on Apple, Spotify, or your favorite podcast app for weekly conversations with today's global leaders that will dominate the 21st century in fintech, business, and beyond.Do you prefer a written summary? Check out the Fintech Leaders newsletter and join 60,000+ readers and listeners worldwide!Miguel Armaza is Co-Founder and General Partner of Gilgamesh Ventures, a seed-stage investment fund focused on fintech in the Americas. He also hosts and writes the Fintech Leaders podcast and newsletter.Miguel on LinkedIn: https://bit.ly/3nKha4ZMiguel on Twitter: https://bit.ly/2Jb5oBcFintech Leaders Newsletter: bit.ly/3jWIp
This time, Collin's venturing solo brings you a special episode where he dives into his top tool picks from 2023. The year was a remarkable journey, filled with experimentation and embracing new methodologies that significantly impacted our sales and marketing approach. Let's explore the essential tools that made a mark: Apollo, Clay, ChatGPT, and Orum. Highlights include: The Biggest Risk Predictable Revenue Took in 2023 (01:45), What is Clay? (9:40), Do I Need to Explain Why I Love GPT? (16:55), What We Love about Orum! (18:50), and more... Are you looking to create repeatable, scalable, and predictable revenue? We can help! ► https://bit.ly/predictablerevenuecoaching
Community, customer experience, and content that aids in the development process are all not exclusive to the fintech industry, but our guest on this show has a TON of experience in that space. Marketers and more will benefit from our conversation on this one that's a smorgasbord of goodness! :) Learn about... - Community Building: Community should be viewed as more than just a channel or tactic, but as a group of people coming together organically around a brand or culture. Our guest shares his experiences, including when he was working at moov, where community was at the core of the company's DNA. - Sales & Marketing Collaboration: The discussion emphasizes the need for sales and marketing teams to work closely together. This collaboration helps bridge the gap between customer needs and company objectives. - Customer Experience (CX): Marketers can respond to customer needs while also aligning with the company's goals. Defining the customer journey and aligning on goals are essential steps in providing a great customer experience. Our guest... Bryan McCarty Bryan is the Director of Marketing at Orum, the simplest API for fast, reliable payments. As a B2B fintech marketing leader, Bryan has been the founding marketer for several successful brands, including Banno (acquired by Jack Henry in 2014), Moov, and Hummingbird. As a connector at heart, Bryan gives back to the fintech marketing community through his passion project, FintechMarketers.com, a free job board helping fintech marketers discover the best fintech marketing jobs. ~._.*._.~ Take our LISTENER Community Survey!!! HERE Making a Marketer is here to give our guests a platform and to provide oodles of value to YOU, our listener! Check out episode 141! And share if you enjoy our show. Let us know what you think (again, link above!) https://bit.ly/mamITuneNEW ::: This episode is made possible by Powers of Marketing - emPOWERing amazing podcast experiences & online and in person events ::: **ALSO: Our editor Avri makes amazing music! Check out his music on Spotify!**
This episode is the audio from our recent webinar on the state of cold calling in 2024. We were joined by Greg Alexander, Jr. of ZoomInfo and Colin Specter of Orum. We discuss how the most successful sales teams on the planet are leveraging the phones to pack their pipeline full of qualified opportunities. Check out the show notes, more free content, and get coaching at https://outboundsquad.com
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/CHJ865. CME/MOC/AAPA credit will be available until January 5, 2025.Modern Practice Principles: A Practical “How-To” Guide for Selection, Sequencing, and Optimal Use of HER2-Targeted Therapies in HER2-Positive Breast Cancer In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, GRASP, and Living Beyond Breast Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Seagen Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerSara A. Hurvitz, MD, FACP, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Ambrx; Arvinas, Inc.; AstraZeneca; Bayer Corporation; Celcuity, Inc.; Cytomx Therapeutics, Inc.; Daiichi-Sankyo Inc.; Dantari; Dignitana AB; G1 Therapeutics, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; GlaxoSmithKline; Greenwich Life Sciences Inc; Immunomedics, Inc; Lilly; Loxo Oncology; Macrogenics, Inc.; Novartis Pharmaceuticals Corporation; OBI Pharma, Inc.; Orinove Inc.; Orum; Pfizer; Phoenix Molecular Designs; Pieris Pharmaceuticals, Inc.; Puma Biotechnology, Inc.; Radius Health, Inc.; Sanofi; Seattle Genetics, Inc./Seagen Inc.; and Zymeworks Inc.Speaker for Curio and OncLive.Stock Shareholder in RomTech, spouse.Faculty/PlannerJavier Cortes, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Bioasis Technologies, Inc.; BioInvent International AB; Boehringer Ingelheim Pharmaceuticals, Inc.; Clovis Oncology; Daiichi Sankyo Co., Ltd; Ellipses Pharma; ExpreS2ion Biotechnologies ApS; F. Hoffmann-La Roche Ltd; GEMoaB GmbH; Gilead Sciences, Inc.; HiberCell; Jazz Pharmaceuticals, Inc.; Leuko Labs Inc.; Lilly; The Menarini Group; Merck Sharp & Dohme LLC; REVEAL GENOMICS, S.L.; Scorpion Therapeutics, Inc.; Seattle Genetics; and Zymeworks BC Inc.Grant/Research Support from ARIAD Pharmaceuticals, Inc.; AstraZeneca; Baxalta GmbH/LES LABORATOIRES SERVIER; Bayer Corporation; Eisai Inc.; F. Hoffmann-La Roche Ltd; Guardant Health; IQVIA Inc.; Merck Sharp & Dohme LLC; Pfizer; PIQUR Therapeutics; and Queen Mary University of London.Honoraria from AstraZeneca; Daiichi Sankyo Co., Ltd; Eisai Inc.; F. Hoffmann-La Roche Ltd; Gilead Sciences, Inc.; Lilly; Merck Sharp & Dohme LLC; Novartis AG; Pfizer; and Stemline Therapeutics.Faculty/PlannerPaolo Tarantino, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Gilead, and Lilly.Grant/Research Support from AstraZeneca.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/CHJ865. CME/MOC/AAPA credit will be available until January 5, 2025.Modern Practice Principles: A Practical “How-To” Guide for Selection, Sequencing, and Optimal Use of HER2-Targeted Therapies in HER2-Positive Breast Cancer In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, GRASP, and Living Beyond Breast Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Seagen Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerSara A. Hurvitz, MD, FACP, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Ambrx; Arvinas, Inc.; AstraZeneca; Bayer Corporation; Celcuity, Inc.; Cytomx Therapeutics, Inc.; Daiichi-Sankyo Inc.; Dantari; Dignitana AB; G1 Therapeutics, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; GlaxoSmithKline; Greenwich Life Sciences Inc; Immunomedics, Inc; Lilly; Loxo Oncology; Macrogenics, Inc.; Novartis Pharmaceuticals Corporation; OBI Pharma, Inc.; Orinove Inc.; Orum; Pfizer; Phoenix Molecular Designs; Pieris Pharmaceuticals, Inc.; Puma Biotechnology, Inc.; Radius Health, Inc.; Sanofi; Seattle Genetics, Inc./Seagen Inc.; and Zymeworks Inc.Speaker for Curio and OncLive.Stock Shareholder in RomTech, spouse.Faculty/PlannerJavier Cortes, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Bioasis Technologies, Inc.; BioInvent International AB; Boehringer Ingelheim Pharmaceuticals, Inc.; Clovis Oncology; Daiichi Sankyo Co., Ltd; Ellipses Pharma; ExpreS2ion Biotechnologies ApS; F. Hoffmann-La Roche Ltd; GEMoaB GmbH; Gilead Sciences, Inc.; HiberCell; Jazz Pharmaceuticals, Inc.; Leuko Labs Inc.; Lilly; The Menarini Group; Merck Sharp & Dohme LLC; REVEAL GENOMICS, S.L.; Scorpion Therapeutics, Inc.; Seattle Genetics; and Zymeworks BC Inc.Grant/Research Support from ARIAD Pharmaceuticals, Inc.; AstraZeneca; Baxalta GmbH/LES LABORATOIRES SERVIER; Bayer Corporation; Eisai Inc.; F. Hoffmann-La Roche Ltd; Guardant Health; IQVIA Inc.; Merck Sharp & Dohme LLC; Pfizer; PIQUR Therapeutics; and Queen Mary University of London.Honoraria from AstraZeneca; Daiichi Sankyo Co., Ltd; Eisai Inc.; F. Hoffmann-La Roche Ltd; Gilead Sciences, Inc.; Lilly; Merck Sharp & Dohme LLC; Novartis AG; Pfizer; and Stemline Therapeutics.Faculty/PlannerPaolo Tarantino, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Gilead, and Lilly.Grant/Research Support from AstraZeneca.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/CHJ865. CME/MOC/AAPA credit will be available until January 5, 2025.Modern Practice Principles: A Practical “How-To” Guide for Selection, Sequencing, and Optimal Use of HER2-Targeted Therapies in HER2-Positive Breast Cancer In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, GRASP, and Living Beyond Breast Cancer. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Seagen Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerSara A. Hurvitz, MD, FACP, has a financial interest/relationship or affiliation in the form of:Grant/Research Support from Ambrx; Arvinas, Inc.; AstraZeneca; Bayer Corporation; Celcuity, Inc.; Cytomx Therapeutics, Inc.; Daiichi-Sankyo Inc.; Dantari; Dignitana AB; G1 Therapeutics, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; GlaxoSmithKline; Greenwich Life Sciences Inc; Immunomedics, Inc; Lilly; Loxo Oncology; Macrogenics, Inc.; Novartis Pharmaceuticals Corporation; OBI Pharma, Inc.; Orinove Inc.; Orum; Pfizer; Phoenix Molecular Designs; Pieris Pharmaceuticals, Inc.; Puma Biotechnology, Inc.; Radius Health, Inc.; Sanofi; Seattle Genetics, Inc./Seagen Inc.; and Zymeworks Inc.Speaker for Curio and OncLive.Stock Shareholder in RomTech, spouse.Faculty/PlannerJavier Cortes, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Bioasis Technologies, Inc.; BioInvent International AB; Boehringer Ingelheim Pharmaceuticals, Inc.; Clovis Oncology; Daiichi Sankyo Co., Ltd; Ellipses Pharma; ExpreS2ion Biotechnologies ApS; F. Hoffmann-La Roche Ltd; GEMoaB GmbH; Gilead Sciences, Inc.; HiberCell; Jazz Pharmaceuticals, Inc.; Leuko Labs Inc.; Lilly; The Menarini Group; Merck Sharp & Dohme LLC; REVEAL GENOMICS, S.L.; Scorpion Therapeutics, Inc.; Seattle Genetics; and Zymeworks BC Inc.Grant/Research Support from ARIAD Pharmaceuticals, Inc.; AstraZeneca; Baxalta GmbH/LES LABORATOIRES SERVIER; Bayer Corporation; Eisai Inc.; F. Hoffmann-La Roche Ltd; Guardant Health; IQVIA Inc.; Merck Sharp & Dohme LLC; Pfizer; PIQUR Therapeutics; and Queen Mary University of London.Honoraria from AstraZeneca; Daiichi Sankyo Co., Ltd; Eisai Inc.; F. Hoffmann-La Roche Ltd; Gilead Sciences, Inc.; Lilly; Merck Sharp & Dohme LLC; Novartis AG; Pfizer; and Stemline Therapeutics.Faculty/PlannerPaolo Tarantino, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Gilead, and Lilly.Grant/Research Support from AstraZeneca.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
In this episode of "The Goats of Growth," I had the pleasure of sitting down with Colin Spector, the VP of Sales at Orum—an innovative AI-powered live conversation platform. We dive deep into a discussion about the core skills essential for success in sales, such as grit, curiosity, and care, and Colin shared invaluable insights into how he nurtures these qualities within his team. A key highlight was Colin emphasizing the significance of leaders actively listening to their team members' ideas. A must listen for leaders with ambitions of growing their team. Colins Linkedin Page Developing Sales Skills and Empowerment (00:04:05) Colin discusses the importance of grit, curiosity, and care in sales reps, and how to empower them to think outside the box and improve their skills. The reason for pattern interrupt (00:11:09) Colin explains how using an engineer as a salesperson was a pattern interrupt that led to more successful meetings. The importance of attitude and activity (00:14:05) Colin discusses the two levers that can be controlled every day: attitude and activity, and how they contribute to success in sales. Caring and champion building (00:18:03) Colin emphasizes the importance of caring for customers and building champions by helping them solve their problems and achieve their goals. Taking care of each other in business (00:22:12) Discussion about the importance of taking care of employees, sales reps, and customers in order to create a positive work environment. Big goal: Purchasing a rental property in Portugal (00:23:06) Colin's goal of buying a rental property in Portugal that can be used as a vacation property for his family. Learning new information through immersion(00:24:24) Colin's preferred way of learning new information, including languages and industries, by immersing himself in the culture and language.
Terry Husayn (Talha), VP of Technical engagement and a member of the founding team at Orum. In this part Terry spoke about the process of building an early stage sales team - from the ground up. Specifically we focused on hiring, training and creating compensation plans for BDRs and SDRs. Some mentions from the episode: Winning an SDR interview, Terry's blog Betts recruiting - recruiting AlwaysHired - SDR school Shift Group - shiftgroup.io - recruiting Terry's LinkedIn: https://www.linkedin.com/in/talhahusayn/ Link to Orum: https://www.orum.com/ And of course, keep an eye out on our articles through SubStack that you can check out here.
Terry Husayn (Talha), VP of Technical engagement and a member of the founding team at Orum in this episode talks about the following: - intro to cold-calling, who needs to do it and why - testing of the outreach strategy - specifics of outreach Databases of emails/phone numbers: Zoominfo Apollo LeadIQ Lusha Intent based signals tracking can be done here: Sixth Sense Tool to capture your website visitors: Warmly Terry's LinkedIn: https://www.linkedin.com/in/talhahusayn/ Link to Orum: https://www.orum.com/ And of course, keep an eye out on our articles through SubStack that you can check out here.
In the rapidly changing landscape of sales, it's crucial to keep up-to-date with the best techniques for success. On this episode, Collin Stewart sat down with Drew Kluender, Senior Inside Sales Rep at Orum, to discuss the nuanced art of sales, specifically over the phone. From building a foolproof cold-calling script to mastering the art of objection handling, this in-depth conversation offers a treasure trove of insights for SDRs at every stage of their career. Highlights include: How do you break down a cold-call script? (0:40), What if they say no? (9:53), How to add value after the accusation audit (11:33), “We're currently using [competition], and it's working fine” (22:18), and more… Are you looking to create repeatable, scalable, and predictable revenue? We can help! ► https://bit.ly/predictablerevenuecoaching
This episode is the audio from our recent webinar on AE Self-Sourcing. We were joined by Terry Husayn, VP of Technical Engagement at Orum. Connect with Terry Husayn and Orum. Check out the show notes, more free content, and get coaching at https://outboundsquad.com
Our expert hosts Kate Moody is joined by some great guests to talk about the most notable fintech, financial services and banking news from the past week. This week's guests include: Stephany Kirkpatrick, CEO & Founder at Orum Mandy Beech, Director of Retail Services at Nationwide Uneesa Zaman, CEO of UneesaFinance We cover the following stories from the fintech and financial services space: Orum launch a first-of-its-kind account verification tool for FedNow Metro Bank find a way out... and a new controller shareholder Nationwide unveil their first major rebrand in 36 years A new open-banking lending platform comes to Bahrain Spanish banks trial a digital Euro US politican George Santos faces charges of wire fraud and money laundering Fintech Insider by 11:FS is a bi-weekly podcast dedicated to all things finance, banking, technology, and financial services. Our expert hosts, with real industry experience, are joined by the biggest decision-makers, VCs, and reporters from across financial services including guests from Visa, Nubank, M-Pesa, Techcrunch, Starling, and JP Morgan Chase to discuss the latest news, developments, and trends within the industry. Our weekly news show drops every Monday and tackles the biggest news stories, from acquisitions and launches, to regulatory changes and innovation. Then, every Friday our Insights show dives deeper into the hottest topics shaping the industry like web3 and BNPL. Whether you're already immersed in the world of financial services, or just keen to learn more, this is the #1 podcast for you. If you enjoyed this episode, don't forget to subscribe and please leave a review Follow us on Twitter: @fintechinsiders where you can ask the hosts questions, or email podcasts@11fs.com! Special Guests: Mandy Beech, Stephany Kirkpatrick, and Uneesa Zaman.
Join FPC Executive Director Reed Luhtanen as he goes off the rails with Stephany Kirkpatrick of Orum. Stephany and Reed talk about Orum's new account verification product, the prospect of building innovations on top of faster payments rails, artificial intelligence, and bringing more girls into STEM. Please complete the Faster Payments for Financial Inclusion Survey, find the link at the top of the page on www.fasterpaymentscouncil.org!
Why do some courts and lawyers instinctively react to examinations under oath (EUOs), also called sworn statements, as if they're "secret depositions?" When conducted properly, they clearly aren't. But the issue still arises from time to time. In this episode Garrity talks about two recent court rulings. One is from a Florida federal judge that rejected an effort to have the court treat EUOs and depositions as one and the same. The other, from South Carolina, sanctioned a defendant for taking an EUO that the court said in essence was the very deposition the court had forbidden. Garrity offers some fantastic thoughts and tips for conducting EUOs in a way that mnimizes the risk a court will confuse them with depositions, which are an intellectually and procedurally different animal.SHOW NOTESFed. R. Civ. P. 30, Depositions by Oral Examination (main federal deposition rule, outlining the procedural requirements for an oral examination to constitute a deposition)Order Denying Defendant's Motion to Strike Sworn Statement, etc. Jett v. Del Toro, Case No. 5:22-cv-90-MW-MJF, Docket No. 46, (N. D. Fla. Sep. 21, 2023) (rejecting argument that a sworn statement taken with a court reporter under oath is a deposition; further, “The traditional practice of securing affidavits for use in support of summary judgment often involves a statement written by counsel specifically for that purpose, which is then presented to and signed by the affiant. This Court fails to see how an unedited transcription of the witness's own words, is not, if anything, substantially more reliable than the traditional alternative”)Defendant's Motion to Strike, etc., Jett v. Del Toro, Case No. 5:22-cv-90-MW-MJF, Docket No. 38, (N. D. Fla. filed August 11, 2023) (unsuccessfully arguing that sworn statements or EUO's “are simply unnoticed depositions”)Reed v. Aetna Casualty and Surety Company, Inc., 160 F.R.D. 572 (N.D. Ind. Mar. 29, 1995) (rejecting motion to strike statement of plaintiff conducted by plaintiff's counsel under oath and before a court reporter; rejecting arguments that statement could not be considered because it wasn't signed by the plaintiff, contained leading questions, and was taken without defendant having the opportunity to cross-examine the witness, saying defendant was in the same position it would have been if an affidavit by the witness had been filed, as the defendant would not have been able to cross-examine the affidavit, either)Bozeman v. Orum, 422 F.3d 1265 (11th Cir. 2005) (rejecting argument that statement made under oath before court reporter was inadmissible for summary judgment purposes because it was neither signed nor taken in the presence of defendants lawyers to allow cross-examination; held, “We reject this argument. Sworn statements given before court reporters or at least as reliable as signed affidavits and are properly considered on summary judgment”)Glenn v. 3M Co., 440 S.C. 34, 95, 890 S.E.2d 569, 602 (Ct. App. 2023), reh'g denied (Aug. 10, 2023) (sanctioning counsel for taking “sworn statement” of witness whose deposition court had prohibited, where statement was under oath, was “in the question-and-answer format typical of a deposition,” and taken before a reporter and at the same day and time as the proposed deposition the court has prohibited; held, “. . . Fisher Controls wholly disregarded this [c]ourt's order prohibiting Dr. Timothy Oury's deposition. Although Fisher Controls labeled the deposition a “sworn statement,” the statement is clearly a deposition submitted under a label which would not immediately invoke the [c]ourt's ire. The statement was transcribed by an official [c]ourt [r]eporter on the day and at the time that Fisher Controls had originally scheduled Dr. Oury's deposition—a deposition prohibited by an Order of Protection from this [c]ourt.”)Defendant's Memorandum in Opposition to Protective Order, Zorn v. Principal Life Insurance Company, No. 6:09-CV-00081-BAE-GRS, 2010 WL 4253299 (S.D.Ga. July 22, 2010) (“Plaintiff also asserts that because he underwent an examination under oath (EUO) during the claims process, he should somehow be exempt from a deposition in his own, subsequent lawsuit. Plaintiff cites no authority for this position, and the case law is to the contrary. See Kamin v. Central States Fire Ins. Co., 22 F.R.D. 220 (E.D.N.Y. 1958) (denying motion for protective order to preclude depositions on the grounds that EUOs had been taken); Oreman Sales, Inc. v. State Farm Fire & Casualty Co., 1991 WL 87936 (E.D. La. May 23, 1991) (same); Sentry Ins. v. Shivers, 164 F.R.D. 255, 256 (D. Kan. 1996) (“Taking a statement of a party, sworn or unsworn, pursuant to investigating a claim or potential lawsuit, does not equate with deposing him or her.”); Joe's Market Fish, Inc. v. Scottsdale Ins. Co., 1998 WL 851504 (N.D. Ill. Dec. 3, 1998) (“an examination under oath does not immunize an individual from a later deposition”); Jones v. State Farm Fire & Casualty Co., 129 F.R.D. 170 (N.D. Ind. Jan. 2, 1990)(“Undoubtedly State Farm now has information which was not available at the time of the examination under oath.”)St. Francis Hosp., Inc. v. Grp. Hosp. Serv., 598 P.2d 238, 240–41 (Okla. 1979) (saying a “[d]eposition has been defined by various jurisdictions as being confined to the written testimony of a witness given in the course of a judicial proceeding in advance of the trial or hearing, upon oral examination or in response to written interrogatories where an opportunity for cross-examination is given”)Brooks v. Tate, No. 1:11-CV-01503 AWI, 2013 WL 4049053, at *1 (E.D. Cal. Aug. 7, 2013) (“By definition , “a ‘deposition' is the examination under oath by ‘oral questions' of a party or deponent.” Paige v. Consumer Programs, Inc., 248 F.R.D. 272, 275 (C.D.Cal.2008). A party who wants to depose a person by oral questions must give written notice to every other party, stating the time and place of the deposition. Fed.R.Civ.P. 30(b)(1). “Where a deponent is not a party to the action, he can be compelled to appear at a deposition examination only by issuance of a subpoena” pursuant to Rule 45. Cleveland v. Palmby, 75 F.R.D. 654, 656 (W.D.Okl.1977). “Unless the parties stipulate otherwise, a deposition must be conducted before an officer appointed or designated under Rule 28.” Fed.R.Civ.P. 30(b)(5)(A).”)Paige v. Consumer Programs, Inc., 248 F.R.D. 272, 275 (C.D. Cal. 2008) (“Considering Rule 30 as a whole, and affording the words in that rule their plain meaning, as we must, see Business Guides, Inc. v. Chromatic Communications Enterprises, Inc., 498 U.S. 533, 540, 111 S.Ct. 922, 928, 112 L.Ed.2d 1140 (1991) (“ ‘We give the Federal Rules of Civil Procedure their plain meaning.' ” (quoting Pavelic & LeFlore v. Marvel Entertainment Group, 493 U.S. 120, 123, 110 S.Ct. 456, 458, 107 L.Ed.2d 438 (1989))); Kootenai Tribe of Idaho v. Veneman, 313 F.3d 1094, 1111 (9th Cir.2002) (“As a rule of construction, Federal Rules of Civil Procedure are given their plain meaning.”), it is clear that a deposition is the examination under oath by “oral questions” of a party or deponent. In other words, a party who merely appears for a deposition that does not take place has not “been deposed” since he has not been examined by oral questions”)Chicago Coliseum Club v. Dempsey, 8 Pa. D. & C. 420, 420–21 (Com. Pl. 1926) (“The definition of a deposition will be found in 1 Bouvier's Law Dictionary, 848, as follows: “The testimony of a witness reduced to writing, in due form of law, by virtue of a commission or other authority of a competent tribunal, or according to the provisions of some statute law, to be used on the trial of some question of fact in a court of justice”)
We sit down with the 2023 MVP Open Champ Matt Orum, for an unforgettable interview.Topics:4:03-29:32 MVP Open Recap29:33-1:22:40 Matty O Interview1:22:41-1:31:05 MVP Open FPO Recap1:31:11-1:35:30 Champions Cup News1:35:31-1:39:20 Tour Championship Update1:39:21-1:41:15 United States Women's Disc Golf Championship1:42:46-1:48:00 HousekeepingWatch the show live Tuesday nights at 8PM EST here: http://bit.ly/FoundationPodcasts
This episode was produced remotely using the ListenDeck standardized audio & video production system. If you're looking to jumpstart your podcast miniseries or upgrade your podcast or video production please visit www.ListenDeck.com. You can subscribe to this podcast and stay up to date on all the stories here on Apple Podcasts, Google Podcasts, Stitcher, Spotify, Amazon and iHeartRadio. In this episode the host John Siracusa chats remotely with Stephany Kirkpatrick, Co-founder & CEO at Orum. Orum provides an API integration for fast, reliable payments. A solution to access RTP, ACH, Same Day ACH, and more. We're off until Sept14th. Subscribe now on Apple Podcasts, Google Podcasts, Stitcher, Spotify, Amazon and iHeartRadio and get notified when we release our next episode on September 14th! About the host: John is the founder of ListenDeck a full-service podcast and video production company, which has produced over 1000 episodes of various podcasts. He is the host of the ‘Bank On It' podcast, which features over 500 episodes starring high profile fintech leaders and entrepreneurs. Follow John on LinkedIn, Twitter, Medium
In the most recent episode of the podcast "Hidden Killers," host Tony Brueski delves deep into the chilling case of Thomas Randolph, accused of murdering his sixth wife and a friend. The twist? Randolph claims it was all done in self-defense. The episode highlights an intriguing pre-trial hearing that took place two months ago. Brueski prefaces the hearing, remarking on the peculiar nature of Randolph's persona: "I think it's important to take a listen and understand more about the very bizarre personality of Thomas Randolph." The audio from the hearing paints a picture of courtroom drama interwoven with layers of complexity surrounding Randolph's case. The hearing takes place virtually, with Mr. Randolph logging in from the Nevada Department of Corrections. The list of attendees include Mr. Randolph's counsel, Mr. Oro and Mr. Orum, and Mr. Pesci, representing the state. One of the significant concerns raised during the session is Randolph's access to his lawyers. He fervently expresses his frustration: "It's beyond me that my lawyers... Cannot set up a virtual [call]... this is getting old really fast." Randolph then emphasizes his dire need for lawyer-client communication, expressing that after 14 years and 25 different lawyers, he's more than weary. He states with certainty, "This case is over. It's just a matter of filing a couple of motions and the state's not gonna be happy with it." Another contentious point is Randolph's request to be transported to his lawyer's office to review evidence vital to his case. He pleads, "There are literally hundreds of pictures and dozens of hours of video and audio that I have to listen to... I haven't seen the whole walkthrough just because I've had 25 lawyers in 14 years..." The judge, however, asserts that such a transport request is out of her jurisdiction and up to the prison's discretion. But there are also notable lapses in communication; Mr. Oro, Randolph's lawyer, claims they've been facing difficulties even connecting with Randolph via phone, given the prison's policies. To this, the judge replies, "I signed it May 18th, saying that he's supposed to have weekly telephonic conferences with you and Mr. Orno. Are you saying that is not being complied with?" She further emphasizes the need to have the prison authorities present in the courtroom to clarify the miscommunication and ensure compliance with her orders. There's a striking moment when Randolph passionately conveys his conviction that once his lawyers see the evidence he's holding, they'll file the appropriate motions, and in turn, "ruin" both the judge and the state's day. "Then you are going to grant these motions that they file and I'm going home," he claims. As the discussion draws to a close, Randolph inquires about material from Crime Stoppers that his attorneys are expected to receive, to which the judge confirms that the court order for it will be signed. Want to listen to ALL of our podcasts AD-FREE? Subscribe through APPLE PODCASTS, and try it for three days free: https://tinyurl.com/ycw626tj Follow Our Other Cases: https://www.truecrimetodaypod.com The latest on Catching the Long Island Serial Killer, Chad & Lori Daybell, The Murder of Ana Walshe, Alex Murdaugh, Bryan Kohberger, Lucy Letby, Kouri Richins, Justice for Harmony Montgomery, The Murder of Stephen Smith, The Murder of Madeline Kingsbury, and much more! Listen at https://www.truecrimetodaypod.com
All areas of fintech are changing fast. But it is in payments where the most groundbreaking changes are happening right now. After years of development, we finally saw the launch of FedNow last month (on time!) as this country begins its transition to instant payments in earnest.My next guest on the Fintech One-on-One podcast is Stephany Orum, the CEO and Co-Founder of Orum. I wanted to get her back on the show (she was last on in 2021) to discuss FedNow and what it is going to mean for the payments landscape. Orum works with several banks that are part of FedNow and they provide an infrastructure layer for most payments rails.In this podcast you will learn:How Stephany describes Orum today.How banks and fintechs should think about the various payments rails.An explanation of payments orchestration.Why FedNow is a game changer for faster payments.Some of the advantages of FedNow.Feedback from some of the participating banks operating in FedNow's first week.Why it is more important for banks to work on receiving first for FedNow.How the mindset is changing inside banks towards a real-time operation.What the Fed has learned from the experience of RTP.Why interoperability between instant payment rails is inevitable.The role of the other types of payment rails.How banks and fintechs can combat fraud in an instant payments world.What it will mean for the country when most payments are instant.Connect with Stephany on LinkedInConnect with Orum on LinkedInConnect with Fintech One-on-One: Tweet me @PeterRenton Connect with me on LinkedIn Find previous Fintech One-on-One episodes
This episode is the audio from our recent webinar on objection handling. We were joined by Armand Farrokh from 30 Minutes To President's Club and Taylor O'Brien from Orum. Check out the show notes, more free content, and get coaching at https://outboundsquad.com/
This episode is the audio from our recent webinar on how to self-source more pipeline as an Account Executive. We were joined by enterprise AE Avi Mesh and his Sales Director Daisy Chung from Orum. Connect with Avi Mesh, Daisy Chung and Orum. Check out the show notes, more free content, and get coaching at https://OutboundSquad.com
Bill Orum is a Partner at Capricorn Investment Group, one of the largest and longest standing mission-aligned investment organizations. Capricorn oversees $9 billion across three distinct but related investment strategies - an OCIO serving families and foundations, a seeding business that backs impact asset managers, and the Technology Impact Fund, a venture capital fund focused on clean technology and climate solutions. Bill joined Capricorn twenty years ago in the firm's infancy with the mission to deliver extraordinary investment results by leveraging market forces to scale solutions to global problems with a focus on the climate. Our conversation covers the establishment of an investment program to match the Capricorn's mission, universe of available investment opportunities to address climate solutions, and Capricorn's strategy to implement. We discuss seeding new funds, venture capital, emerging markets, public markets, current opportunities, and the potential for a long-term solution for the world. Learn More Follow Ted on Twitter at @tseides or LinkedIn Subscribe to the mailing list Access Transcript with Premium Membership
© 2020-2025 Ivy Podcast Discovery LLC
